Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases

Eight presentations on SPR741 at ECCMID, collectively supporting its activity, safety and tolerability CAMBRIDGE, Mass. , April 16, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and


Leave a Reply

Your email address will not be published.